Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 25 versus SERPASIL ESIDRIX 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 25 versus SERPASIL ESIDRIX 2.
ALDORIL 25 vs SERPASIL-ESIDRIX #2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.
None Documented
None Documented
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Reserpine: 50-100 hours (biphasic; terminal phase 11-16 days due to slow release from adrenergic storage sites); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment).
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Reserpine: 60% renal (as metabolites), 40% fecal (as parent drug and metabolites); Hydrochlorothiazide: >95% renal (unchanged) via tubular secretion.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination